Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft

Cancer Res. 1990 Jan 15;50(2):284-7.

Abstract

Based on previous work demonstrating the activity of cyclophosphamide and melphalan in a series of human medulloblastoma and rhabdomyosarcoma cell lines and transplantable xenografts, investigations were conducted to define the effects of combining cyclophosphamide or melphalan with VP-16. These studies demonstrated a synergistic interaction between cyclophosphamide and VP-16 and melphalan and VP-16 in the treatment of the human rhabdomyosarcoma cell line TE-671 growing in athymic mice. The combination of cyclophosphamide or melphalan with VP-16 may warrant consideration as a therapeutic strategy for solid tumors sensitive to bifunctional alkylating agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkylating Agents / administration & dosage
  • Alkylating Agents / pharmacology*
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / pharmacology*
  • DNA, Neoplasm / drug effects
  • Drug Synergism
  • Etoposide / administration & dosage
  • Etoposide / pharmacology*
  • Female
  • Male
  • Melphalan / administration & dosage
  • Melphalan / pharmacology*
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • Rhabdomyosarcoma / drug therapy*
  • Transplantation, Heterologous

Substances

  • Alkylating Agents
  • DNA, Neoplasm
  • Etoposide
  • Cyclophosphamide
  • Melphalan